Using real-world data, the FDA aims to predict randomized trial results before they’re done

The project aims to help the FDA systematize the use healthcare databases in estimating a product's safety and efficacy for supplemental new drug applications. (Andrew Harnik, Associated Press)

The FDA is taking new steps to test the capabilities of real-world evidence, by attempting to predict the results of randomized, controlled trials before they are completed.

It’s an awaited expansion of the agency’s demonstration project, currently being conducted with the data analytics firm Aetion and Brigham and Women’s Hospital.

The RCT DUPLICATE program originally looked to replicate 30 previously completed clinical trials using real-world data. Now, it aims to prognosticate the outcomes of seven ongoing postmarket studies—a first for the field, according to Aetion.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

"This project will play a major role in determining the future of how drugs are developed and approved," Aetion CEO Carolyn Magill said in a statement. "Data collected from the front lines of clinical care can often provide a more complete picture on how treatments affect patients not represented in clinical trials, but the regulatory process must ensure transparency."

The project’s ultimate goal, of course, is to assist the FDA’s continuing development of standards for using real-world evidence in regulatory decisions—namely, it will help identify when and where healthcare databases can provide proper estimates of safety and efficacy for supplemental new drug applications.

"Predicting the results of clinical trials before they're completed is important for showing that in certain circumstances real-world evidence could potentially substitute for a trial," said project lead Jessica Franklin, Ph.D., assistant professor of medicine at Harvard Medical School and a biostatistician at Brigham and Women's Hospital. "This additional work will be vital as we develop a process model for the implementation of regulatory-grade RWE studies." ­

RELATED: Aetion closes on $27M extension of series B financing to expand its real-world evidence platform

Researchers will register the seven additional phase 4 studies on, and give the FDA direct access to all study components, processes and results, according to Aetion, which is training FDA staff on its platform.

In addition—through a grant funded by the NIH’s National Heart, Lung, and Blood Institute—the program is conducting real-world data analyses on more than 25 cardiovascular studies, including ongoing phase 4 trials and published phase 3 and 4 trials.

The RCT DUPLICATE project—mandated by the 21st Century Cures Act and funded by the FDA's Center for Drug Evaluation and Research—expects to see interim results by mid-2019 and full results by the end of 2020.

Suggested Articles

The response rate was lower in the ONCOS-102 arm than the control cohort, but Targovax saw positives elsewhere.

The €13.9 million series B round will fund a phase 1/2 trial of a therapeutic vaccine in patients with non-small cell lung cancer.

Precision oncology firm Notable Labs is launching its first self-sponsored clinical trial, designed from the ground up to help validate its platform.